As of January 22, 2025, ADC Therapeutics (ADCT) has a market cap of $0.17 billion USD. According to our data, ADC Therapeutics is ranked No.7285 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 22, 2025 | $0.17 B |
-14.07%
|
Dec 31, 2024 | $0.19 B |
19.88%
|
Dec 29, 2023 | $0.16 B |
-56.77%
|
Dec 30, 2022 | $0.37 B |
-80.99%
|
Dec 31, 2021 | $1.95 B |
-36.89%
|
Dec 31, 2020 | $3.10 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
Mersana Therapeutics
MRSN
|
$66.09 M |
0.000 M
|
USA
|
BioAtla
BCAB
|
$28.89 M |
0.000 M
|
USA
|
Sutro Biopharma
STRO
|
$0.16 B |
-0.000 M
|
USA
|
Zymeworks
ZYME
|
$0.98 B |
-0.000 M
|
Canada
|
Genmab
GMAB
|
$13.37 B |
0.000 M
|
Denmark
|
MacroGenics
MGNX
|
$0.19 B |
0.000 M
|
USA
|
Pieris Pharmaceuticals
PIRS
|
$17.96 M |
0.000 M
|
USA
|
CytomX Therapeutics
CTMX
|
$65.38 M |
0.000 M
|
USA
|
Nektar Therapeutics
NKTR
|
$0.16 B |
0.000 M
|
USA
|
ADC Therapeutics
ADCT
|
$0.17 B |
0.000 M
|
Switzerland
|
Market Cap | = | ADCT Stock Price | * | ADCT Shares Outstanding |
= | $1.71 | * | 96.69 M | |
= | $0.17 B |